论文部分内容阅读
本文采用马洛替酯以随机双盲法治疗35例慢性肝炎和代偿期肝硬化患者。治疗组18例,对照组17例,应用马洛替酯口服(治疗组每片含100mg,对照组每片含5mg),60kg以上6片/d,50kg以上5片/d,40kg以上4片/d,分2次服,3mo为一个疗程。结果表明该药对ALT,TTT和乙肝5项指标无影响,但对升高血清白蛋白和降低γ球蛋白有作用。该药口服方便,可作为慢性肝疾病提高白蛋白及降低γ球蛋白的治疗药物。
In this paper, 35 cases of chronic hepatitis and compensated liver cirrhosis were treated with randomized double-blind therapy. 18 cases in the treatment group and 17 cases in the control group were treated with oral malondialid (100mg per treatment group, 5mg per one control group), 6 / 60kg or more, 5 / 50kg / d, 4kg / / d, 2 times service, 3mo for a course of treatment. The results show that the drug has no effect on ALT, TTT and hepatitis B five indicators, but the increase of serum albumin and reduce the role of gamma globulin. The drug is convenient for oral administration and can be used as a therapeutic drug for improving albumin and reducing gamma globulin in chronic liver diseases.